Yang Jingyuan, Li Xiaoli, Tan Jing, Zhou Ping, Hu Lingjun, Chen Jie, Li Tingyu, Liu Yonggang, Chen Li
Growth, Development and Mental Health Center of Children and Adolescents, Chongqing Key Laboratory of Child Neurodevelopment and Cognitive Disorders, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Children's Hospital of Chongqing Medical University, Chongqing, 400014, China.
Yibin Hospital Affiliated to Children's Hospital of Chongqing Medical University, Yibin, 644000, China.
Neurochem Res. 2025 Apr 17;50(3):146. doi: 10.1007/s11064-025-04398-8.
Autism spectrum disorder (ASD) involves a complex neurodevelopmental pathogenesis. A disintegrin and metalloproteinase 10 (ADAM10) plays a crucial role in embryonic brain development and neural network stability. This study aimed to investigate the influence of ADAM10 on excitation/inhibition (E/I) balance, autism-like behaviors, and learning and memory dysfunction in rats prenatally exposed to valproic acid (VPA) and determine potential intervention strategies. The VPA-exposed group exhibited increased levels of ADAM10 and secreted amyloid precursor protein-α (sAPPα). Moreover, overexpression of glutamate decarboxylase 1 and N-methyl-D-aspartate receptors was observed. High-performance liquid chromatography-mass spectrometry revealed elevated levels of glutamate, glutamine, and γ-aminobutyric acid, as well as an E/I imbalance in the VPA group. Additionally, narrower synaptic clefts as well as increased postsynaptic density and synaptic vesicles were observed. Remarkably, intraperitoneal administration of ADAM10 inhibitor during the critical period of synaptic development significantly improved ASD-like behavior and learning and memory function in VPA-exposed rats. This intervention effectively reduced abnormally high sAPPα levels in the prefrontal cortex and corrected abnormal E/I balance. Thus, inhibiting ADAM10 overexpression may improve the E/I imbalance, alleviate core symptoms of ASD, and improve learning and memory dysfunction. The use of ADAM10 inhibitor represents a potential therapeutic strategy for treating ASD patients with intellectual disabilities.
自闭症谱系障碍(ASD)涉及复杂的神经发育发病机制。解整合素金属蛋白酶10(ADAM10)在胚胎脑发育和神经网络稳定性中起关键作用。本研究旨在探讨ADAM10对产前暴露于丙戊酸(VPA)的大鼠的兴奋/抑制(E/I)平衡、自闭症样行为以及学习和记忆功能障碍的影响,并确定潜在的干预策略。VPA暴露组的ADAM10和分泌型淀粉样前体蛋白-α(sAPPα)水平升高。此外,还观察到谷氨酸脱羧酶1和N-甲基-D-天冬氨酸受体的过表达。高效液相色谱-质谱分析显示VPA组谷氨酸、谷氨酰胺和γ-氨基丁酸水平升高,以及E/I失衡。此外,还观察到突触间隙变窄以及突触后致密物和突触小泡增加。值得注意的是,在突触发育的关键期腹腔注射ADAM10抑制剂可显著改善VPA暴露大鼠的ASD样行为以及学习和记忆功能。这种干预有效地降低了前额叶皮质中异常高的sAPPα水平,并纠正了异常的E/I平衡。因此,抑制ADAM10过表达可能改善E/I失衡,减轻ASD的核心症状,并改善学习和记忆功能障碍。使用ADAM10抑制剂代表了一种治疗患有智力障碍的ASD患者的潜在治疗策略。
Brain Res Bull. 2025-1
Cochrane Database Syst Rev. 2021-9-3
J Hazard Mater. 2025-5-5
Annu Rev Clin Psychol. 2025-5
Cell Mol Biol Lett. 2025-1-15
Behav Brain Res. 2025-1-5